

# NIPS TEST

Non-invasive DNA screening test for fetal chromosomal abnormalities

## Introducing Greenarray's non-invasive prenatal screening -GENERA


**GENERA** non-invasive prenatal screening is the latest addition to our group of services for expectant moms and will provide you with rapid, accurate results about the health of your unborn child.

### What is the **GENERA** non-invasive prenatal tests?

**GENERA** is non-invasive prenatal test that screens for fetal chromosomal abnormalities which can affect its future health. NIPS uses a mother's blood sample to determine the chances of a chromosomal condition in unborn child. **GENERA** - a highly accurate test that avoids the risk of miscarriage associated with invasive procedures such as chorionic villus sampling (CVS) or amniocentesis.

### How does **GENERA** work?

During pregnancy, some of the fetal DNA crosses the placenta into the bloodstream. **GENERA** tests this DNA to determine the chance that the fetus has chromosomal abnormalities. These abnormalities are caused by extra or missing chromosomes that cause miscarriage or a child with mental or physical disabilities.



### What does **GENERA-NIPS** screen for?

- Down syndrome (trisomy 21)
- Edwards syndrome (trisomy 18)
- Patau syndrome (trisomy 13)

### Who should be Tested?

- ✓ Any pregnant woman above 10 weeks of pregnancy.
- ✓ Women with advance maternal age.
- ✓ Couples with family history of genetic disorders.
- ✓ Couples who have child with genetic disorder.
- ✓ Couples who have undergone IVF Pregnancy.
- ✓ Ultrasound and serum screening showing abnormality.



PCPNDT registered  
(1112/2020)

## GENERA Technology



## Why **GENERA NIPS**?

- Simple and safe** : a one-tube blood test that poses no risk to the fetus.
- Convenient** : available from as early as the 10<sup>th</sup> week of pregnancy.
- Fast results**
- Reliable and accurate**

### Traditional screening test vs. **GENERA NIPS**

**GENERA NIPS** has high test accuracy of 99.9 % as compared to traditional screening test which has accuracy of 75-90 %.

### What is included in the **GENERA** report?

**GENERA** NIPT report includes one of two possible results for chromosomes 21, 18 and 13.

#### Low risk result


This means that it is very unlikely that your pregnancy is affected by the chromosomal conditions screened by the test.

#### High risk result

This means that there is an increased chance that the fetus may have extra or missing copies of one or more chromosomes or parts of chromosomes. Genetic counseling is required for further confirmatory tests like amniocentesis / chorionic villus sampling & to help you understand & evaluate further options.

## Quality Performance of **GENERA** study

Findings of **GENERA** study (June 2021-August 2021)



"In compliance with PCPNDT act of India, prenatal sex determination is not carried out at our lab"

## References

- Chen, K.M., White, K., Shabbeer, J. and Schmid, M., 2019. Maternal age trends support uptake of non-invasive prenatal testing (NIPT) in the low-risk population. The Journal of Maternal-Fetal & Neonatal Medicine. 32(23). pp.4039-4042.
- Walker, B.S., Nelson, R.E., Jackson, B.R., Grenache, D.G., Ashwood, E.R. and Schmid, R.L., 2015. A cost-effectiveness analysis of first trimester non-invasive prenatal screening for fetal trisomies in the United States. PLoS One, 10(7), p.e0131402.

## About Greenarray

Greenarray is a molecular diagnostic company. We offer diagnosis of infectious diseases, genetic testing and healthcare information to improve health and wellness. Our goal is to provide high quality affordable and accessible services.

2nd Floor, Above P.N.Gadgil showroom, Happy colony, Kothrud, Pune- 411038, Maharashtra, India.

+91 98230 49121